Company News
Suven Life Sciences Completes Masupirdine Phase-3 Enrollment
Suven Life Sciences completed patient enrollment for its global Phase-3 study of Masupirdine (SUVN-502) for Alzheimer's agitation treatment.
The study randomized 424 patients across US and European si
